<!DOCTYPE html>
<html lang="cs">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Saxenda vs Ozempic vs Wegovy vs Mounjaro: srovnÃ¡nÃ­ ÃºÄinnosti a rozdÃ­lÅ¯ | Slim Medi Diget</title>
  <meta name="description" content="DÅ¯kladnÃ© srovnÃ¡nÃ­ liraglutidu (Saxenda), semaglutidu (Ozempic/Wegovy) a tirzepatidu (Mounjaro). Mechanismus, dÃ¡vkovÃ¡nÃ­, ÃºÄinnost a graf redukce vÃ¡hy za 18 mÄ›sÃ­cÅ¯.">

  <!-- Open Graph meta tagy -->
  <meta property="og:title" content="Saxenda vs Ozempic vs Wegovy vs Mounjaro: srovnÃ¡nÃ­ ÃºÄinnosti a rozdÃ­lÅ¯">
  <meta property="og:description" content="Liraglutid vs semaglutid vs tirzepatid pÅ™ehlednÄ›: mechanismus, dÃ¡vkovÃ¡nÃ­, ÃºÄinnost, neÅ¾Ã¡doucÃ­ ÃºÄinky a graf vÃ¡hovÃ©ho poklesu za 18 mÄ›sÃ­cÅ¯.">
  <meta property="og:url" content="https://med-digest-bot.lovable.app/clanek/srovnani-saxenda-ozempic-wegovy-mounjaro">
  <meta property="og:type" content="article">
  <meta property="og:locale" content="cs_CZ">
  <meta property="og:site_name" content="Slim Medi Diget">

  <!-- Twitter Card -->
  <meta name="twitter:card" content="summary_large_image">
  <meta name="twitter:title" content="Saxenda vs Ozempic vs Wegovy vs Mounjaro">
  <meta name="twitter:description" content="SrovnÃ¡nÃ­ GLP-1 lÃ©kÅ¯ a tirzepatidu: ÃºÄinnost, rozdÃ­lÅ¯ a graf za 18 mÄ›sÃ­cÅ¯.">

  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">

  <style>
    :root {
      --bg-primary: #0f0f23;
      --bg-secondary: #1a1a2e;
      --bg-card: #16162a;
      --bg-card-alt: #1e1e3a;
      --text-primary: #f8fafc;
      --text-secondary: #94a3b8;
      --text-muted: #64748b;
      --border-color: #2d2d4a;
      --accent-purple: #a855f7;
      --accent-purple-soft: rgba(168, 85, 247, 0.15);
      --accent-green: #10b981;
      --accent-green-soft: rgba(16, 185, 129, 0.15);
      --accent-blue: #3b82f6;
      --accent-blue-soft: rgba(59, 130, 246, 0.15);
      --accent-amber: #f59e0b;
      --accent-amber-soft: rgba(245, 158, 11, 0.15);
      --gradient-hero: linear-gradient(135deg, #1a1a2e 0%, #16162a 50%, #1e1e3a 100%);
      --shadow-card: 0 4px 24px rgba(0, 0, 0, 0.3);
      --radius: 12px;
    }

    @media (prefers-color-scheme: light) {
      :root {
        --bg-primary: #f8fafc;
        --bg-secondary: #f1f5f9;
        --bg-card: #ffffff;
        --bg-card-alt: #f8fafc;
        --text-primary: #0f172a;
        --text-secondary: #475569;
        --text-muted: #64748b;
        --border-color: #e2e8f0;
        --accent-purple-soft: rgba(168, 85, 247, 0.1);
        --accent-green-soft: rgba(16, 185, 129, 0.1);
        --accent-blue-soft: rgba(59, 130, 246, 0.1);
        --accent-amber-soft: rgba(245, 158, 11, 0.1);
        --gradient-hero: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 50%, #e2e8f0 100%);
        --shadow-card: 0 4px 24px rgba(0, 0, 0, 0.08);
      }
    }

    * { margin: 0; padding: 0; box-sizing: border-box; }
    body {
      font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
      background: var(--bg-primary);
      color: var(--text-primary);
      line-height: 1.6;
      min-height: 100vh;
    }
    .container { max-width: 900px; margin: 0 auto; padding: 0 1.5rem; }

    header {
      background: var(--gradient-hero);
      padding: 3rem 0 4rem;
      border-bottom: 1px solid var(--border-color);
    }
    .badge-row { display: flex; flex-wrap: wrap; gap: 0.5rem; margin-bottom: 1.5rem; }
    .badge {
      display: inline-flex; align-items: center; gap: 0.375rem;
      padding: 0.375rem 0.75rem; border-radius: 9999px;
      font-size: 0.75rem; font-weight: 500;
      background: var(--accent-purple-soft); color: var(--accent-purple);
    }
    .badge.green { background: var(--accent-green-soft); color: var(--accent-green); }
    .badge.blue  { background: var(--accent-blue-soft);  color: var(--accent-blue); }
    .badge.amber { background: var(--accent-amber-soft); color: var(--accent-amber); }

    h1 {
      font-size: clamp(1.75rem, 4vw, 2.5rem);
      font-weight: 700; line-height: 1.2; margin-bottom: 0.75rem;
      background: linear-gradient(135deg, var(--accent-purple) 0%, var(--accent-green) 100%);
      -webkit-background-clip: text; -webkit-text-fill-color: transparent;
      background-clip: text;
    }
    .subtitle {
      font-size: clamp(1rem, 2vw, 1.25rem);
      color: var(--text-secondary);
      margin-bottom: 1.5rem;
    }
    .pills { display: flex; flex-wrap: wrap; gap: 0.5rem; }
    .pill {
      display: inline-block;
      padding: 0.375rem 0.875rem;
      background: var(--bg-card);
      border: 1px solid var(--border-color);
      border-radius: 9999px;
      font-size: 0.8125rem;
      color: var(--text-secondary);
    }

    main { padding: 3rem 0; }

    .kpi-section { margin-bottom: 3rem; }
    .kpi-section-title {
      font-size: 1rem; font-weight: 600; color: var(--text-muted);
      text-transform: uppercase; letter-spacing: 0.05em;
      margin-bottom: 1.25rem; text-align: center;
    }
    .kpi-grid { display: grid; grid-template-columns: repeat(2, 1fr); gap: 1rem; }
    @media (max-width: 600px) { .kpi-grid { grid-template-columns: 1fr; } }

    .kpi-card {
      background: var(--bg-card);
      border: 1px solid var(--border-color);
      border-radius: var(--radius);
      padding: 1.25rem;
      display: flex;
      align-items: center;
      gap: 1rem;
      box-shadow: var(--shadow-card);
    }
    .kpi-card.purple { border-left: 4px solid var(--accent-purple); }
    .kpi-card.green  { border-left: 4px solid var(--accent-green); }
    .kpi-card.blue   { border-left: 4px solid var(--accent-blue); }
    .kpi-card.amber  { border-left: 4px solid var(--accent-amber); }

    .kpi-icon {
      width: 48px; height: 48px; border-radius: 12px;
      display: flex; align-items: center; justify-content: center;
      font-size: 1.5rem; flex-shrink: 0;
    }
    .kpi-icon.purple { background: var(--accent-purple-soft); }
    .kpi-icon.green  { background: var(--accent-green-soft); }
    .kpi-icon.blue   { background: var(--accent-blue-soft); }
    .kpi-icon.amber  { background: var(--accent-amber-soft); }

    .kpi-content { flex: 1; }
    .kpi-label {
      font-size: 0.75rem; color: var(--text-muted);
      text-transform: uppercase; letter-spacing: 0.05em;
      margin-bottom: 0.25rem;
    }
    .kpi-value {
      font-size: 1rem; font-weight: 600; color: var(--text-primary);
    }

    .card {
      background: var(--bg-card);
      border: 1px solid var(--border-color);
      border-radius: var(--radius);
      padding: 1.75rem;
      margin-bottom: 1.5rem;
      box-shadow: var(--shadow-card);
    }
    .card-header { display: flex; align-items: center; gap: 0.75rem; margin-bottom: 1.25rem; }
    .card-icon {
      width: 40px; height: 40px; border-radius: 10px;
      display: flex; align-items: center; justify-content: center;
      font-size: 1.25rem;
    }
    .card-icon.purple { background: var(--accent-purple-soft); }
    .card-icon.green  { background: var(--accent-green-soft); }
    .card-icon.blue   { background: var(--accent-blue-soft); }
    .card-icon.amber  { background: var(--accent-amber-soft); }

    .card-title { font-size: 1.25rem; font-weight: 600; color: var(--text-primary); }
    .card p { color: var(--text-secondary); margin-bottom: 1rem; }
    .card p:last-child { margin-bottom: 0; }

    .card ul { list-style: none; margin: 1rem 0; }
    .card li { position: relative; padding-left: 1.5rem; margin-bottom: 0.625rem; color: var(--text-secondary); }
    .card li::before { content: "â†’"; position: absolute; left: 0; color: var(--accent-purple); font-weight: 600; }

    .note-box {
      background: var(--bg-card-alt);
      border: 1px solid var(--border-color);
      border-left: 4px solid var(--accent-purple);
      border-radius: var(--radius);
      padding: 1rem 1.25rem;
      margin-top: 1.25rem;
    }
    .note-box.green { border-left-color: var(--accent-green); }
    .note-box.amber { border-left-color: var(--accent-amber); }
    .note-box.blue  { border-left-color: var(--accent-blue); }

    .note-box-label {
      font-size: 0.75rem; font-weight: 600; color: var(--accent-purple);
      text-transform: uppercase; letter-spacing: 0.05em;
      margin-bottom: 0.375rem;
    }
    .note-box.green .note-box-label { color: var(--accent-green); }
    .note-box.amber .note-box-label { color: var(--accent-amber); }
    .note-box.blue  .note-box-label { color: var(--accent-blue); }
    .note-box-content { font-size: 0.9375rem; color: var(--text-primary); font-style: italic; }

    .clinical-box {
      background: var(--accent-blue-soft);
      border-radius: var(--radius);
      padding: 1rem 1.25rem;
      margin-top: 1rem;
    }
    .clinical-box-title {
      font-size: 0.8125rem; font-weight: 600;
      color: var(--accent-blue); margin-bottom: 0.5rem;
    }
    .clinical-box ul { margin: 0; }
    .clinical-box li { color: var(--text-primary); }
    .clinical-box li::before { color: var(--accent-blue); }

    .table-wrapper {
      overflow-x: auto;
      margin: 1.5rem 0;
      border-radius: var(--radius);
      border: 1px solid var(--border-color);
    }
    table { width: 100%; border-collapse: collapse; font-size: 0.875rem; }
    th, td {
      padding: 0.875rem 1rem;
      text-align: left;
      border-bottom: 1px solid var(--border-color);
    }
    th {
      background: var(--bg-card-alt);
      font-weight: 600;
      color: var(--text-primary);
      white-space: nowrap;
    }
    td { color: var(--text-secondary); }
    tr:last-child td { border-bottom: none; }
    tr:hover td { background: var(--bg-card-alt); }

    .summary-box {
      background: linear-gradient(135deg, var(--accent-purple-soft) 0%, var(--accent-green-soft) 100%);
      border: 1px solid var(--border-color);
      border-radius: var(--radius);
      padding: 1.5rem;
      margin: 2rem 0;
      text-align: center;
    }
    .summary-box p {
      font-size: 1.0625rem;
      color: var(--text-primary);
      font-weight: 500;
      margin: 0;
    }

    /* Simple chart wrapper */
    .chart-wrap {
      background: var(--bg-card-alt);
      border: 1px solid var(--border-color);
      border-radius: var(--radius);
      padding: 1rem 1.25rem;
      margin-top: 1rem;
    }
    .chart-legend {
      display: flex;
      flex-wrap: wrap;
      gap: 0.5rem;
      margin-top: 0.75rem;
      color: var(--text-secondary);
      font-size: 0.875rem;
    }
    .legend-item {
      display: inline-flex;
      align-items: center;
      gap: 0.5rem;
      padding: 0.375rem 0.75rem;
      border: 1px solid var(--border-color);
      border-radius: 9999px;
      background: var(--bg-card);
    }
    .legend-item.bold { font-weight: 700; color: var(--text-primary); } /* <-- (3) */

    .swatch {
      width: 10px;
      height: 10px;
      border-radius: 9999px;
      background: var(--text-muted);
    }
    .swatch.purple { background: var(--accent-purple); }
    .swatch.green  { background: var(--accent-green); }
    .swatch.blue   { background: var(--accent-blue); }
    .swatch.amber  { background: var(--accent-amber); }

    .sources {
      margin-top: 3rem;
      padding-top: 2rem;
      border-top: 1px solid var(--border-color);
    }
    .sources-title {
      font-size: 1rem; font-weight: 600; color: var(--text-primary);
      margin-bottom: 1rem; display: flex; align-items: center; gap: 0.5rem;
    }
    .source-list { list-style: none; }
    .source-list li {
      padding: 0.625rem 0;
      border-bottom: 1px solid var(--border-color);
      font-size: 0.875rem;
      color: var(--text-secondary);
    }
    .source-list li:last-child { border-bottom: none; }
    .source-author { font-weight: 500; color: var(--text-primary); }
    .source-journal { font-style: italic; color: var(--text-muted); }

    footer {
      padding: 2rem 0;
      border-top: 1px solid var(--border-color);
      text-align: center;
    }
    .disclaimer {
      font-size: 0.8125rem;
      color: var(--text-muted);
      max-width: 600px;
      margin: 0 auto;
    }

    .two-col {
      display: grid;
      grid-template-columns: repeat(2, 1fr);
      gap: 1.5rem;
    }
    @media (max-width: 768px) { .two-col { grid-template-columns: 1fr; } }

    a { color: inherit; text-decoration: underline; text-decoration-color: rgba(255,255,255,0.25); }
    a:hover { text-decoration-color: rgba(255,255,255,0.6); }
  </style>
</head>

<body>
  <header>
    <div class="container">
      <div class="badge-row">
        <span class="badge">ğŸ§¬ Slim Medi Diget</span>
        <span class="badge">GLP-1</span>
        <span class="badge green">GIP + GLP-1</span>
        <span class="badge blue">Edukace</span>
        <span class="badge amber">SrovnÃ¡nÃ­ lÃ©kÅ¯</span>
      </div>

      <h1>Saxenda vs Ozempic vs Wegovy vs Mounjaro</h1>
      <p class="subtitle">Liraglutid â€¢ Semaglutid (diabetes vs obezita) â€¢ Tirzepatid â€” rozdÃ­ly, ÃºÄinnost a graf za 18 mÄ›sÃ­cÅ¯</p>

      <div class="pills">
        <span class="pill">Mechanismus ÃºÄinku</span>
        <span class="pill">DÃ¡vkovÃ¡nÃ­</span>
        <span class="pill">OÄekÃ¡vanÃ½ Ãºbytek vÃ¡hy</span>
        <span class="pill">NeÅ¾Ã¡doucÃ­ ÃºÄinky</span>
        <span class="pill">PraktickÃ© tipy</span>
      </div>
    </div>
  </header>

  <main>
    <div class="container">

      <!-- Intro -->
      <div class="card">
        <div class="card-header">
          <div class="card-icon blue">ğŸ’¡</div>
          <h2 class="card-title">Ãšvod: proÄ se tyto lÃ©ky poÅ™Ã¡d pletou</h2>
        </div>
        <p>KlÃ­ÄovÃ© je pochopit, Å¾e <strong>Ozempic a Wegovy majÃ­ stejnou ÃºÄinnou lÃ¡tku (semaglutid)</strong>, ale liÅ¡Ã­ se <strong>indikacÃ­ a dÃ¡vkami</strong>. ZatÃ­mco Mounjaro (tirzepatid) je <strong>dual-agonista</strong> (GLP-1 + GIP), coÅ¾ Äasto znamenÃ¡ nejvyÅ¡Å¡Ã­ prÅ¯mÄ›rnou ÃºÄinnost na vÃ¡hu.</p>
      </div>

      <!-- KPI Section -->
      <section class="kpi-section">
        <h3 class="kpi-section-title">KlÃ­ÄovÃ© rozdÃ­ly na prvnÃ­ pohled</h3>
        <div class="kpi-grid">
          <div class="kpi-card purple">
            <div class="kpi-icon purple">ğŸ•’</div>
            <div class="kpi-content">
              <div class="kpi-label">Saxenda (liraglutid)</div>
              <div class="kpi-value">DennÃ­ injekce</div>
            </div>
          </div>

          <div class="kpi-card blue">
            <div class="kpi-icon blue">ğŸ“†</div>
            <div class="kpi-content">
              <div class="kpi-label">Ozempic / Wegovy / Mounjaro</div>
              <div class="kpi-value">TÃ½dennÃ­ injekce</div>
            </div>
          </div>

          <div class="kpi-card amber">
            <div class="kpi-icon amber">âš–ï¸</div>
            <div class="kpi-content">
              <div class="kpi-label">PrÅ¯mÄ›rnÃ½ Ãºbytek vÃ¡hy (RCT)</div>
              <div class="kpi-value">~8% vs ~15% vs ~21%</div>
            </div>
          </div>

          <div class="kpi-card green">
            <div class="kpi-icon green">ğŸ§©</div>
            <div class="kpi-content">
              <div class="kpi-label">Mechanismus</div>
              <div class="kpi-value">GLP-1 vs GLP-1+GIP</div>
            </div>
          </div>
        </div>
      </section>

      <!-- Two column: Saxenda + Ozempic -->
      <div class="two-col">
        <div class="card">
          <div class="card-header">
            <div class="card-icon purple">ğŸ’‰</div>
            <h2 class="card-title">Saxenda = liraglutid (GLP-1 RA)</h2>
          </div>
          <p><strong>Liraglutid</strong> je â€prvnÃ­ velkÃ¡ vlnaâ€œ GLP-1 lÃ©Äby obezity. Funguje spolehlivÄ›, ale mÃ¡ dvÄ› nevÃ½hody: <strong>dennÃ­ injekce</strong> a obvykle <strong>niÅ¾Å¡Ã­ prÅ¯mÄ›rnÃ½ Ãºbytek vÃ¡hy</strong> neÅ¾ modernÄ›jÅ¡Ã­ molekuly.</p>
          <ul>
            <li>Mechanismus: agonista GLP-1 receptoru (sytost, menÅ¡Ã­ pÅ™Ã­jem energie)</li>
            <li>DÃ¡vkovÃ¡nÃ­: dennÄ›, titrace do 3.0 mg</li>
            <li>ÃšÄinnost (obezita): prÅ¯mÄ›rnÄ› ~<strong>âˆ’8%</strong> ve 56. tÃ½dnu (NEJM 2015)</li>
            <li>TypickÃ© NÃš: nauzea, zvracenÃ­, zÃ¡cpa/prÅ¯jem (Äasto pÅ™i rychlÃ© titraci)</li>
          </ul>

          <div class="note-box">
            <div class="note-box-label">ğŸ“Œ Prakticky</div>
            <div class="note-box-content">â€Saxenda je Äasto volba tam, kde nenÃ­ dostupnÃ½ / vhodnÃ½ vyÅ¡Å¡Ã­ vÃ½kon (Wegovy/Mounjaro), nebo kde nÄ›kdo lÃ©pe snÃ¡Å¡Ã­ dennÃ­ reÅ¾im.â€œ</div>
          </div>
        </div>

        <div class="card">
          <div class="card-header">
            <div class="card-icon blue">ğŸ©º</div>
            <h2 class="card-title">Ozempic = semaglutid (GLP-1 RA, diabetes)</h2>
          </div>
          <p><strong>Ozempic</strong> je semaglutid primÃ¡rnÄ› pro diabetes 2. typu. V praxi se Äasto Å™eÅ¡Ã­ i jeho â€vedlejÅ¡Ã­â€œ efekt: <strong>Ãºbytek vÃ¡hy</strong>. Ten je ale typicky menÅ¡Ã­ neÅ¾ u Wegovy, protoÅ¾e jde o jinÃ© dÃ¡vkovÃ¡nÃ­/indikaci.</p>
          <ul>
            <li>Mechanismus: agonista GLP-1 receptoru</li>
            <li>DÃ¡vkovÃ¡nÃ­: tÃ½dnÄ›, bÄ›Å¾nÄ› 0.5â€“1.0 mg (nÄ›kde i vyÅ¡Å¡Ã­ dle lokÃ¡lnÃ­ho schvÃ¡lenÃ­)</li>
            <li>
              ÃšÄinnost na vÃ¡hu: ve studii (semaglutid 1.0 mg) poklesla hmotnost ve 30. tÃ½dnu prÅ¯mÄ›rnÄ› o
              <strong>âˆ’4,53 kg</strong>. PÅ™i prÅ¯mÄ›rnÃ© vstupnÃ­ vÃ¡ze ~91,9 kg je to zhruba <strong>~âˆ’4,9 %</strong>.
              (<a href="https://pubmed.ncbi.nlm.nih.gov/28110911/" target="_blank" rel="noreferrer">Sorli et al., 2017</a>)
            </li>
            <li>TypickÃ© NÃš: GIT podobnÄ› jako u ostatnÃ­ch GLP-1</li>
          </ul>

          <div class="note-box blue">
            <div class="note-box-label">ğŸ“Œ Pozor na zÃ¡mÄ›nu</div>
            <div class="note-box-content">â€Ozempic â‰  Wegovy. StejnÃ¡ ÃºÄinnÃ¡ lÃ¡tka, ale jinÃ© dÃ¡vky a cÃ­lovÃ¡ indikace.â€œ</div>
          </div>
        </div>
      </div>

      <!-- Two column: Wegovy + Mounjaro -->
      <div class="two-col">
        <div class="card">
          <div class="card-header">
            <div class="card-icon amber">ğŸ·ï¸</div>
            <h2 class="card-title">Wegovy = semaglutid (GLP-1 RA, obezita)</h2>
          </div>
          <p><strong>Wegovy</strong> je semaglutid v dÃ¡vkÃ¡ch a titraci navrÅ¾enÃ½ch pÅ™Ã­mo pro lÃ©Äbu obezity. V RCT studiÃ­ch jde o <strong>vÃ½raznÃ½ prÅ¯mÄ›rnÃ½ Ãºbytek vÃ¡hy</strong> a standard modernÃ­ GLP-1 lÃ©Äby obezity.</p>
          <ul>
            <li>Mechanismus: GLP-1 receptor agonista (silnÃ½ efekt na sytost, chuÅ¥, pÅ™Ã­jem energie)</li>
            <li>DÃ¡vkovÃ¡nÃ­: tÃ½dnÄ›, titrace aÅ¾ na 2.4 mg</li>
            <li>ÃšÄinnost (obezita): prÅ¯mÄ›rnÄ› <strong>âˆ’14.9%</strong> ve 68. tÃ½dnu (STEP 1, NEJM 2021)</li>
            <li>NÃš: GIT, nÄ›kdy nutnÃ¡ pomalejÅ¡Ã­ titrace</li>
          </ul>
        </div>

        <div class="card">
          <div class="card-header">
            <div class="card-icon green">ğŸš€</div>
            <h2 class="card-title">Mounjaro = tirzepatid (GLP-1 + GIP)</h2>
          </div>
          <p><strong>Tirzepatid</strong> kombinuje ÃºÄinek na <strong>GLP-1 receptor</strong> a <strong>GIP receptor</strong>. V praxi to Äasto znamenÃ¡ nejvyÅ¡Å¡Ã­ prÅ¯mÄ›rnou ÃºÄinnost na vÃ¡hu v celÃ© â€inkretinovÃ©â€œ tÅ™Ã­dÄ›.</p>
          <ul>
            <li>Mechanismus: dual-agonista (GLP-1 + GIP)</li>
            <li>DÃ¡vkovÃ¡nÃ­: tÃ½dnÄ›, titrace (napÅ™. 5 / 10 / 15 mg v RCT)</li>
            <li>ÃšÄinnost (obezita): prÅ¯mÄ›rnÄ› aÅ¾ <strong>âˆ’20.9%</strong> ve 72. tÃ½dnu (15 mg, SURMOUNT-1, NEJM 2022)</li>
            <li>NÃš: podobnÄ› jako GLP-1 (GIT), Äasto pomÅ¯Å¾e pomalejÅ¡Ã­ titrace</li>
          </ul>
        </div>
      </div>

      <!-- Comparison table -->
      <div class="card">
        <div class="card-header">
          <div class="card-icon blue">ğŸ“Š</div>
          <h2 class="card-title">SrovnÃ¡nÃ­ pÅ™ehlednÄ›</h2>
        </div>

        <div class="table-wrapper">
          <table>
            <thead>
              <tr>
                <th>LÃ©k (znaÄka)</th>
                <th>ÃšÄinnÃ¡ lÃ¡tka</th>
                <th>Indikace</th>
                <th>Receptory</th>
                <th>Frekvence</th>
                <th>RCT Ãºbytek vÃ¡hy (orientaÄnÄ›)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Saxenda</td>
                <td>Liraglutid</td>
                <td>Obezita</td>
                <td>GLP-1</td>
                <td>DennÄ›</td>
                <td><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1411892" target="_blank" rel="noreferrer">~âˆ’8% / 56 tÃ½dnÅ¯ (NEJM 2015)</a></td>
              </tr>
              <tr>
                <td>Ozempic</td>
                <td>Semaglutid</td>
                <td>Diabetes 2</td>
                <td>GLP-1</td>
                <td>TÃ½dnÄ›</td>
                <td><a href="https://pubmed.ncbi.nlm.nih.gov/28110911/" target="_blank" rel="noreferrer">~âˆ’4,53 kg (~âˆ’4,9%) / 30 tÃ½dnÅ¯ (1.0 mg)</a></td>
              </tr>
              <tr>
                <td>Wegovy</td>
                <td>Semaglutid</td>
                <td>Obezita</td>
                <td>GLP-1</td>
                <td>TÃ½dnÄ›</td>
                <td><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2032183" target="_blank" rel="noreferrer">~âˆ’14.9% / 68 tÃ½dnÅ¯ (NEJM 2021)</a></td>
              </tr>
              <tr>
                <td>Mounjaro</td>
                <td>Tirzepatid</td>
                <td>DM2 / (obezita dle zemÄ›)</td>
                <td>GLP-1 + GIP</td>
                <td>TÃ½dnÄ›</td>
                <td><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2206038" target="_blank" rel="noreferrer">~âˆ’20.9% / 72 tÃ½dnÅ¯ (15 mg, NEJM 2022)</a></td>
              </tr>
            </tbody>
          </table>
        </div>
      </div>

      <!-- Chart -->
      <div class="card">
        <div class="card-header">
          <div class="card-icon purple">ğŸ“ˆ</div>
          <h2 class="card-title">Graf: prÅ¯mÄ›rnÃ© snÃ­Å¾enÃ­ hmotnosti za 18 mÄ›sÃ­cÅ¯</h2>
        </div>

        <p>Graf nÃ­Å¾e ukazuje <strong>ilustraÄnÃ­ kÅ™ivky</strong> poklesu vÃ¡hy (v %) pro 4 reÅ¾imy. KÅ™ivky jsou zÃ¡mÄ›rnÄ› â€hladkÃ©â€œ (exponenciÃ¡lnÃ­ saturace), aby odpovÃ­daly typickÃ©mu klinickÃ©mu prÅ¯bÄ›hu: rychlejÅ¡Ã­ zaÄÃ¡tek a postupnÃ© plateau.</p>

        <div class="chart-wrap">
          <svg id="wlChart" viewBox="0 0 860 360" width="100%" height="auto" role="img" aria-label="Graf redukce vÃ¡hy za 18 mÄ›sÃ­cÅ¯">
            <line x1="60" y1="30" x2="60" y2="310" stroke="currentColor" opacity="0.25"/>
            <line x1="60" y1="310" x2="830" y2="310" stroke="currentColor" opacity="0.25"/>
            <g id="grid"></g>

            <polyline id="lineSax" fill="none" stroke="var(--accent-purple)" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" />
            <polyline id="lineOze" fill="none" stroke="var(--accent-blue)" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" />
            <polyline id="lineWeg" fill="none" stroke="var(--accent-amber)" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" />
            <polyline id="lineMou" fill="none" stroke="var(--accent-green)" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" />

            <text x="60" y="22" font-size="12" fill="currentColor" opacity="0.7">Pokles vÃ¡hy (%)</text>
            <text x="760" y="345" font-size="12" fill="currentColor" opacity="0.7">MÄ›sÃ­ce</text>
          </svg>

          <div class="chart-legend">
            <span class="legend-item bold"><span class="swatch purple"></span>Saxenda (liraglutid) â€” cÃ­l ~âˆ’8.5% v 18 mÄ›s.</span>
            <span class="legend-item"><span class="swatch blue"></span>Ozempic (semaglutid) â€” cÃ­l ~âˆ’6% v 18 mÄ›s.</span>
            <span class="legend-item"><span class="swatch amber"></span>Wegovy (semaglutid 2.4) â€” cÃ­l ~âˆ’15.5% v 18 mÄ›s.</span>
            <span class="legend-item"><span class="swatch green"></span>Mounjaro (tirzepatid 15) â€” cÃ­l ~âˆ’21.5% v 18 mÄ›s.</span>
          </div>

          <div class="note-box">
            <div class="note-box-label">ğŸ“Œ Jak ÄÃ­st graf</div>
            <div class="note-box-content">â€Jde o % pokles od startovnÃ­ vÃ¡hy. KÅ™ivky nejsou â€˜slibâ€™, jen prÅ¯mÄ›rnÃ¡ trajektorie z klinickÃ½ch dat + opatrnÃ½ odhad do 18 mÄ›sÃ­cÅ¯.â€œ</div>
          </div>
        </div>
      </div>

      <section class="sources">
        <h3 class="sources-title">ğŸ“š Zdroje</h3>
        <ul class="source-list">
          <li><span class="source-author">Pi-Sunyer X. et al.</span> Randomized trial of liraglutide 3.0 mg in obesity. <span class="source-journal">NEJM, 2015.</span> <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1411892" target="_blank" rel="noreferrer">Link</a></li>
          <li><span class="source-author">Wilding JPH. et al.</span> Semaglutide 2.4 mg once weekly in overweight/obesity (STEP 1). <span class="source-journal">NEJM, 2021.</span> <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2032183" target="_blank" rel="noreferrer">Link</a></li>
          <li><span class="source-author">Jastreboff AM. et al.</span> Tirzepatide once weekly for obesity (SURMOUNT-1). <span class="source-journal">NEJM, 2022.</span> <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2206038" target="_blank" rel="noreferrer">Link</a></li>
          <li><span class="source-author">Sorli C. et al.</span> Once-weekly semaglutide in type 2 diabetes. <span class="source-journal">Lancet Diabetes Endocrinol, 2017.</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28110911/" target="_blank" rel="noreferrer">Link</a></li>
        </ul>
      </section>

    </div>
  </main>

  <footer>
    <div class="container">
      <p class="disclaimer">
        âš ï¸ Tento obsah je urÄen pouze pro informaÄnÃ­ a edukaÄnÃ­ ÃºÄely. Nenahrazuje odbornou lÃ©kaÅ™skou konzultaci, diagnostiku ani lÃ©Äbu. V pÅ™Ã­padÄ› zdravotnÃ­ch obtÃ­Å¾Ã­ se vÅ¾dy poraÄte s lÃ©kaÅ™em.
      </p>
    </div>
  </footer>

  <script>
    const months = Array.from({ length: 19 }, (_, i) => i);

    // ExponenciÃ¡lnÃ­ saturace smÄ›rem k cÃ­lovÃ©mu poklesu:
    // y(m) = target * (1 - exp(-k*m))
    function expCurve(target, k) {
      return months.map(m => target * (1 - Math.exp(-k * m)));
    }

    // cÃ­le pro 18 mÄ›sÃ­cÅ¯ (orientaÄnÄ›)
    const saxenda  = expCurve(-8.5, 0.18);
    const ozempic  = expCurve(-6.0, 0.22);
    const wegovy   = expCurve(-15.5, 0.16);
    const mounjaro = expCurve(-21.5, 0.17);

    const grid = document.getElementById("grid");
    const W = 860, H = 360;
    const padL = 60, padR = 30, padT = 30, padB = 50;
    const x0 = padL, x1 = W - padR;
    const y0 = padT, y1 = H - padB;

    const yMin = -25, yMax = 0;

    function xScale(m) { return x0 + (m / 18) * (x1 - x0); }
    function yScale(v) {
      const t = (v - yMax) / (yMin - yMax); // v=0 =>0 ; v=-25=>1
      return y0 + t * (y1 - y0);
    }
    function toPoints(arr) {
      return arr.map((v, i) => `${xScale(i)},${yScale(v)}`).join(" ");
    }

    // y ticks every 5%
    [0, -5, -10, -15, -20, -25].forEach(val => {
      const y = yScale(val);

      const line = document.createElementNS("http://www.w3.org/2000/svg","line");
      line.setAttribute("x1", x0); line.setAttribute("x2", x1);
      line.setAttribute("y1", y);  line.setAttribute("y2", y);
      line.setAttribute("stroke", "currentColor");
      line.setAttribute("opacity", "0.12");
      grid.appendChild(line);

      const label = document.createElementNS("http://www.w3.org/2000/svg","text");
      label.setAttribute("x", 16);
      label.setAttribute("y", y + 4);
      label.setAttribute("font-size", "12");
      label.setAttribute("fill", "currentColor");
      label.setAttribute("opacity", "0.65");
      label.textContent = `${val}%`;
      grid.appendChild(label);
    });

    // x ticks every 3 months
    [0,3,6,9,12,15,18].forEach(m => {
      const x = xScale(m);

      const line = document.createElementNS("http://www.w3.org/2000/svg","line");
      line.setAttribute("x1", x); line.setAttribute("x2", x);
      line.setAttribute("y1", y0); line.setAttribute("y2", y1);
      line.setAttribute("stroke", "currentColor");
      line.setAttribute("opacity", "0.06");
      grid.appendChild(line);

      const label = document.createElementNS("http://www.w3.org/2000/svg","text");
      label.setAttribute("x", x - 6);
      label.setAttribute("y", H - 20);
      label.setAttribute("font-size", "12");
      label.setAttribute("fill", "currentColor");
      label.setAttribute("opacity", "0.65");
      label.textContent = `${m}`;
      grid.appendChild(label);
    });

    document.getElementById("lineSax").setAttribute("points", toPoints(saxenda));
    document.getElementById("lineOze").setAttribute("points", toPoints(ozempic));
    document.getElementById("lineWeg").setAttribute("points", toPoints(wegovy));
    document.getElementById("lineMou").setAttribute("points", toPoints(mounjaro));
  </script>
</body>
</html>
